The Src homology 3 binding domain is required for lysophosphatidic acid 3 receptor-mediated cellular viability in melanoma cells
Authors:
- 1 January 2015
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 356 (2) , 589-596
Abstract
No abstract availableKeywords
Funding Information
- American Cancer Society (120634-RSG-11-269-01-CDD)
- Georgia Research Alliance
This publication has 27 references indexed in Scilit:
- International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor NomenclaturePharmacological Reviews, 2010
- Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acidMolecular Cancer, 2010
- Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progressionExpert Reviews in Molecular Medicine, 2007
- Of Spiders and Crabs: The Emergence of Lysophospholipids and Their Metabolic Pathways as Targets for Therapy in CancerClinical Cancer Research, 2006
- The emerging role of lysophosphatidic acid in cancerNature Reviews Cancer, 2003
- Apoptosis and melanoma chemoresistanceOncogene, 2003
- Functional Comparisons of the Lysophosphatidic Acid Receptors, LPA1/VZG-1/EDG-2, LPA2/EDG-4, and LPA3/EDG-7 in Neuronal Cell Lines Using a Retrovirus Expression SystemMolecular Pharmacology, 2000
- Lysophosphatidic Acid Inhibits Ca2+ Signaling in Response to Epidermal Growth Factor Receptor Stimulation in Human Astrocytoma Cells by a Mechanism Involving Phospholipase Cγ and a Gαi ProteinJournal of Neurochemistry, 2000
- Molecular Cloning and Characterization of a Lysophosphatidic Acid Receptor, Edg-7, Expressed in ProstateMolecular Pharmacology, 2000
- Molecular Cloning and Characterization of a Novel Human G-protein-coupled Receptor, EDG7, for Lysophosphatidic AcidJournal of Biological Chemistry, 1999